ARHGEF38

Across TCGA pan-cancer cohorts, ARHGEF38 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF38 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARHGEF38 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF38 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, PDAC, and UCEC are the cancer types where ARHGEF38 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.592	0.954	.001	9	view →
PDAC	DFS	Median	II,III,IV	0.320	0.840	.024	6	view →
UCEC	DFS	Tertile	All	1.000	0.826	.040	4	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGEF38–LSCC (DFS)

Open the LSCC breakdown →